CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 8, 2008--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a drug discovery and
development company focused on therapeutics targeting Toll-like
Receptors (TLR), today announced that it will discuss its TLR-targeted
drug discovery and development programs and provide a general corporate
overview at the 10th Annual Massachusetts Biotechnology Investors Forum
on Tuesday, December 9 at 4:20 p.m. (ET) at the Sheraton Hotel in Boston.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious
diseases, autoimmune diseases, cancer, and respiratory diseases, and for
use as vaccine adjuvants. Our proprietary drug candidates are designed
to modulate specific Toll-like Receptors, which are a family of immune
system receptors that direct immune system responses. Our pioneering DNA
and RNA chemistry expertise enables us to create drug candidates for
internal development and generates opportunities for multiple
collaborative alliances. For more information, visit www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties.
For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should,"
"could," "will," "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause the Company's actual results to differ materially from those
indicated by such forward-looking statements, including whether products
based on the Company's technology will advance into or through the
clinical trial process on a timely basis or at all and receive approval
from the United States Food and Drug Administration or equivalent
foreign regulatory agencies; whether, if the Company's products receive
approval, they will be successfully distributed and marketed; whether
the Company's cash resources will be sufficient to fund the its
operations; and such other important factors as are set forth under the
caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q
filed on November 6, 2008, which important factors are incorporated
herein by reference. The Company disclaims any intention or obligation
to update any forward-looking statements.
CONTACT: Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluethje@iderapharma.com
or
MacDougall Biomedical CommunicationsChris Erdman, 781-235-3060
cerdman@macbiocom.com
Source: Idera Pharmaceuticals, Inc.
